Immunmodulation in Patients With HHT

Completed

• Conditions: Hereditary Haemorrhagic Telangiectasia (HHT)

• Registration Number: NCT02983253
• Lead Sponsor: University Hospital, Essen

Brief Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Detailed Description

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Literature and the investigators' observation suggest that HHT is often associated with higher frequency of infectious diseases. This might be a hint for a immunocompromised situation.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-12-02
• Study First Submitted QC: 2016-12-02
• Study First Posted: 2016-12-06
• Primary Completion: 2019-10
• Study Completion: 2019-10
• Status Verified: 2019-12
• Last Update Submitted: 2019-12-18
• Last Update Posted: 2019-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

• aged 18 or over, HHT

Exclusion Criteria

• Unable to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Amounts of leucocytes in patients with HHT	November 2016 - December 2018

Secondary Outcome Measures

Name	Time	Method
Differences in distribution of leucocytes in patients with HHT	November 2016 - December 2018

Trial Locations

Locations (1)

University Hospital Essen; 🇩🇪 Essen, Germany